The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Questcor Pharmaceuticals beat expectations on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share grew significantly.
Margins expanded across the board.
Questcor Pharmaceuticals recorded revenue of $140.3 million. The 12 analysts polled by S&P Capital IQ expected a top line of $129.0 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $59.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.91. The seven earnings estimates compiled by S&P Capital IQ predicted $0.73 per share. GAAP EPS of $0.91 for Q3 were 160% higher than the prior-year quarter's $0.35 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 94.7%, 90 basis points better than the prior-year quarter. Operating margin was 60.1%, 390 basis points better than the prior-year quarter. Net margin was 39.7%, 150 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $134.4 million. On the bottom line, the average EPS estimate is $0.79.
Next year's average estimate for revenue is $471.8 million. The average EPS estimate is $2.75.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 459 members out of 519 rating the stock outperform, and 60 members rating it underperform. Among 130 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 102 give Questcor Pharmaceuticals a green thumbs-up, and 28 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Questcor Pharmaceuticals is outperform, with an average price target of $44.89.
Can your retirement portfolio provide you with enough income to last? You'll need more than Questcor Pharmaceuticals. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add Questcor Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.